📊 SER Key Takeaways
Is Serina Therapeutics, Inc. (SER) a Good Investment?
Serina Therapeutics exhibits critically impaired fundamentals with negative stockholders equity, unsustainable cash burn of $18M annually against only $3.1M cash reserves, and negligible revenue of $130K insufficient to support operations. The company faces imminent solvency risk and will require substantial dilutive financing within months, presenting unacceptable downside risk from a fundamental perspective.
Why Buy Serina Therapeutics, Inc. Stock? SER Key Strengths
- Gross margin of 78.5% demonstrates pricing power on product
- Revenue growth of 132.1% YoY shows positive commercial traction from near-zero base
- Current ratio of 1.71x indicates acceptable short-term liquidity position
SER Stock Risks: Serina Therapeutics, Inc. Investment Risks
- Negative stockholders equity of -$37K indicates balance sheet insolvency
- Operating cash burn of -$18M annually with only 2-3 months of cash runway remaining
- Revenue of $130K is immaterial and insufficient to cover operating expenses of $24M
- Long-term debt of $11.2M cannot be serviced from operating cash flow
- Extreme operating margin of -18,478% reflects pre-commercial biotech losses
- Imminent capital raise requirement will cause substantial shareholder dilution
Key Metrics to Watch
- Cash runway duration and timing of next financing round
- Operating cash burn rate trajectory and path to breakeven
- Revenue growth sustainability and customer acquisition metrics
- Clinical trial progress, FDA decisions, and pipeline advancement
- Debt covenant compliance and refinancing requirements
Serina Therapeutics, Inc. (SER) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Serina Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SER Profit Margin, ROE & Profitability Analysis
SER vs Healthcare Sector: How Serina Therapeutics, Inc. Compares
How Serina Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Serina Therapeutics, Inc. Stock Overvalued? SER Valuation Analysis 2026
Based on fundamental analysis, Serina Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Serina Therapeutics, Inc. Balance Sheet: SER Debt, Cash & Liquidity
SER Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Serina Therapeutics, Inc.'s revenue has declined by 64% over the 5-year period, indicating business contraction. The most recent EPS of $-1.51 indicates the company is currently unprofitable.
SER Revenue Growth, EPS Growth & YoY Performance
SER Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | $1.4M | $0.13 |
| Q2 2025 | $51.0K | $5.2M | $0.51 |
| Q1 2025 | N/A | -$4.8M | $-0.49 |
| Q3 2024 | $14.0K | $1.4M | $0.13 |
| Q2 2024 | $7.0K | $808.0K | $0.11 |
| Q1 2024 | $5.0K | $1.7M | $0.20 |
| Q3 2023 | $9.0K | -$2.4M | $-0.06 |
| Q2 2023 | $9.0K | -$2.6M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Serina Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
SER SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Serina Therapeutics, Inc. (CIK: 0001708599)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SER
What is the AI rating for SER?
Serina Therapeutics, Inc. (SER) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SER's key strengths?
Claude: Gross margin of 78.5% demonstrates pricing power on product. Revenue growth of 132.1% YoY shows positive commercial traction from near-zero base.
What are the risks of investing in SER?
Claude: Negative stockholders equity of -$37K indicates balance sheet insolvency. Operating cash burn of -$18M annually with only 2-3 months of cash runway remaining.
What is SER's revenue and growth?
Serina Therapeutics, Inc. reported revenue of $130.0K.
Does SER pay dividends?
Serina Therapeutics, Inc. does not currently pay dividends.
Where can I find SER SEC filings?
Official SEC filings for Serina Therapeutics, Inc. (CIK: 0001708599) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SER's EPS?
Serina Therapeutics, Inc. has a diluted EPS of $-1.91.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SER a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Serina Therapeutics, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SER stock overvalued or undervalued?
Valuation metrics for SER: ROE of N/A (sector avg: 15%), net margin of -14,755.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SER stock in 2026?
Our dual AI analysis gives Serina Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SER's free cash flow?
Serina Therapeutics, Inc.'s operating cash flow is $-18.0M, with capital expenditures of $59.0K. FCF margin is -13,856.9%.
How does SER compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -14,755.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.71 (avg: 2).